Lorenzo Lobo

Dr. Lorenzo Lobo

Cardiovascular diseases and cardiometabolism department chief. Campo de Mayo, Military Hospital. Argentina
+2
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
GBGabriela Berg
Gabriela Berg
MBMagali Barchuk
Magali Barchuk
LLLorenzo Lobo
Lorenzo Lobo
JNJuan Patricio Nogueira
Juan Patricio Nogueira

24 February 2022 in Advances in Respiratory Medicine
Verified
Journal Article
Open access
LBLeandro Barbagelata
Leandro Barbagelata
WMWalter Masson
Walter Masson
IBIgnacio Bluro
Ignacio Bluro
LLLorenzo Lobo
Lorenzo Lobo
DIDiego Iglesias
Diego Iglesias
GMGraciela Molinero
Graciela Molinero
Introduction: Several studies have evaluated the relation between variables of cardiopulmonary exercise testing (CPET) and major clinical events in pulmonary hypertension (PH) patients, although the results were conflicting. The main objective of this study was to investigate the prognostic value of the CPET derived parameters on all-cause mortality or urgent transplantation in PH patients. Material and Methods: A meta-analysis of time-to-event outcomes were performed from observational studies that evaluated the predictive value of CEPT-related variables [peak oxygen uptake (VO₂) and the ventilation to CO₂ production slope (VE/VCO₂)] in PH patients, reporting data from mortality or urgent transplantation, after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. A random-effects meta-analysis model was then applied. Results: Nine eligible studies, including 986 patients, were identified and considered eligible for the quantitative analyses. This meta-analysis showed that high peak VO₂ was associated with a lower mortality or transplant occurrence (HR: 0.81; 95% CI: 0.78–0.85, I2 = 29%). In addition, high VE/VCO₂ slope was associated with a higher incidence of the primary endpoint (HR: 1.04; 95% CI: 1.02-1.06, I2 = 78%). The sensitivity analysis showed that the results were robust. Conclusions: Our data suggest that in a population with PH the CPET-related variables have predictive capacity regarding mortality and the risk of transplantation. Future studies should establish the best cut-off points for these CPET-related variables.

1 May 2021 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
GMGerardo Masson
Gerardo Masson
GMGraciela Molinero
Graciela Molinero
PCPaola Casciato
Paola Casciato

25 November 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
GGGustavo Giunta
Gustavo Giunta
LBLeandro Barbagelata
Leandro Barbagelata
JNJuan Patricio Nogueira
Juan Patricio Nogueira
Introduction Pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a well-established strategy for achieving substantial reductions in low-density lipoprotein cholesterol (LDL-C). Recently, novel oral PCSK9 inhibitors have emerged, providing new evidence regarding their lipid-lowering efficacy and safety. Methods This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Randomized clinical trials evaluating oral PCSK9 inhibitors and reporting percentage changes in lipid parameters and/or adverse events were included. A qualitative synthesis was performed for all studies meeting predefined eligibility criteria, followed by a quantitative synthesis of studies with sufficient data for statistical pooling. Results Seven randomized clinical trials were included in the qualitative analysis, of which four were eligible for meta-analysis. Five oral PCSK9 inhibitors were identified. Three agents (MK-0616, AZD0780, and NNC0385-0434) contributed to the quantitative analysis, while two (DC371739 and CVI-LM001) were assessed descriptively. Compared with placebo, oral PCSK9 inhibitors significantly reduced LDL-C [mean difference (MD) − 55.7; 95% confidence interval (CI) − 59.3 to − 52.1; I2 = 14%)] and apolipoprotein B (MD − 46.9; 95% CI − 54.6 to − 39.2; I2 = 72.9%). They also lowered non–high-density lipoprotein cholestero (MD − 49.4; 95% CI − 57.4 to − 41.5; I2 = 50.3%), triglycerides (MD − 13.2; 95% CI − 21.4 to − 5.0; I2 = 0%), and lipoprotein(a) (MD − 24.9; 95% CI − 34.9 to − 15.0; I2 = 77.6%). Across trials, no differences in safety outcomes were observed between oral PCSK9 inhibitors and placebo. Conclusion Oral PCSK9 inhibitors demonstrate lipid-lowering efficacy and safety comparable to that of currently approved injectable PCSK9 therapies. These findings support their potential as a convenient and effective alternative, although current evidence remains limited to early-phase studies.

1 November 2019 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
GMGraciela Molinero
Graciela Molinero
EREmiliano Rossi
Emiliano Rossi
Different strategies have been proposed for the cardiovascular risk management of patients with psoriasis. To estimate the cardiovascular risk and evaluate two cardiovascular prevention strategies in patients with psoriasis, analyzing which proportion of patients would be candidates to receive statin therapy. A retrospective cohort was selected from a secondary database. All patients >18 years with psoriasis without cardiovascular disease or lipid-lowering treatment were included. The atherosclerotic cardiovascular disease calculator (2018 American College of Cardiology/American Heart Association guidelines) and the Systematic Coronary Risk Evaluation risk calculator (2016 European Society of Cardiology/European Society of Atherosclerosis guidelines) were calculated. The SCORE risk value was adjusted by a multiplication factor of 1.5. The recommendations for the indication of statins suggested by both guidelines were analyzed. A total of 892 patients (mean age 59.9±16.5 years, 54.5% women) were included. The median atherosclerotic cardiovascular disease calculator and Systematic Coronary Risk Evaluation values were 13.4% (IQR 6.1-27.0%) and 1.9% (IQR 0.4-5.2), respectively. According to the atherosclerotic cardiovascular disease calculator, 20.1%, 11.0%, 32.9%, and 36.4% of the population was classified at low, borderline, moderate, or high risk. Applying the Systematic Coronary Risk Evaluation, 26.5%, 42.9%, 20.8%, and 9.8% of patients were stratified as having low, moderate, high, or very high risk, respectively. The proportion of subjects with statin indication was similar using both strategies: 60.1% and 60.9% for the 2018 American College of Cardiology/American Heart Association and 2016 European Society of Cardiology/European Society of Atherosclerosis guidelines, respectively. This was a secondary database study. Data on the severity of psoriasis and pharmacological treatments were not included in the analysis. This population with psoriasis was mostly classified at moderate-high risk and the statin therapy indication was similar when applying the two strategies evaluated.

3 July 2021 in Acta Cardiologica
Verified
Journal Article
Closed access
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
LBLeandro Barbagelata
Leandro Barbagelata
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
GMGraciela Molinero
Graciela Molinero
Given the complex aetiology and a limited amount of evidence, the medical treatment (including statin use) of myocardial infarction with non-obstructive coronary artery disease (MINOCA) remains unc...